Praemium (ASX: PPS) has posted another strong quarter, with total funds under administration (FUA) hitting a record $62.3 billion, up 17% from the same time last year. The standout this…
Cettire Eyes Q4 Profitability After Volatile Quarter
Luxury e-commerce player keeps market share focus amid global headwinds Cettire (ASX: CTT) has delivered a mixed bag of results in its Q3 FY25 trading update, with revenue holding steady…
Race Oncology Ramps Up Patient Recruitment for RC220 Trial
Second Australian site activated for Phase 1 study in advanced solid tumours Race Oncology (ASX: RAC) has just ticked off another milestone in its Phase 1 clinical trial of RC220,…
Pilbara Minerals March Quarter: Transitioning From Build to Optimise
Pilbara Minerals (ASX: PLS) has delivered its March quarter update, showing it’s well into a transitional phase—wrapping up major expansion works and shifting gears towards optimisation and cost control. While…
Bellevue Gold resets guidance, raises capital to strengthen balance sheet and unlock cash flow
Bellevue Gold (ASX: BGL) has pressed reset on its mine plan, production outlook, and hedge book in a sweeping update aimed at shoring up its balance sheet and positioning the…
Spartan takes full control of Dalgaranga exploration ground with $2.5M buyout
Spartan Resources (ASX: SPR) has moved to consolidate its position at the Dalgaranga Gold Project in WA, snapping up the remaining 20% interest in four exploration tenements it didn’t already…
Orthocell gets green light for Striate+ in Brazil, opening doors to Latin American growth
Orthocell (ASX: OCC) has secured a major regulatory win, with Brazil’s health authority ANVISA granting approval for its dental regeneration product Striate+™. This marks the company’s first regulatory tick in…
GYG delivers strong Q3, ups momentum with new stores and dividend policy
Fast-food challenger Guzman y Gomez (ASX: GYG) has kept the burrito train rolling in Q3 FY25, posting another strong quarter of growth across its global network — and giving investors…
Nuix Eyes Lower End of FY25 ACV Growth Amid Global Uncertainty
Investigative analytics software firm Nuix (ASX: NXL) has flagged a more cautious outlook for the full year, with Annualised Contract Value (ACV) growth now expected to come in at the…
Orthocell Scores Landmark FDA Clearance for Remplir, Opening Doors to US$1.6B Nerve Repair Market
4 April 2025 – Big moment for Perth-based Orthocell (ASX: OCC)—the company has landed 510(k) clearance from the U.S. FDA for its flagship nerve repair device, Remplir™, unlocking access to…